LEADER 02968nam 2200469z- 450 001 9910220053103321 005 20210211 035 $a(CKB)3800000000216246 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/49487 035 $a(oapen)doab49487 035 $a(EXLCZ)993800000000216246 100 $a20202102d2017 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aHLA-G-mediated Immune Tolerance: Past and New Outlooks 210 $cFrontiers Media SA$d2017 215 $a1 online resource (92 p.) 225 1 $aFrontiers Research Topics 311 08$a2-88945-119-4 330 $aThe non-classical HLA class I molecule HLA-G is different from classical HLA class I molecules because of the low polymorphism in the coding region, the fact that HLA-G primary transcript is alternatively spliced in seven isoforms, and the inhibitory action on immune cells. Although HLA-G is low polymorphic, variants in both promoter and 3' un-translated region (UTR) of HLA-G locus regulate its expression. In healthy conditions, a basal level of HLA-G gene transcription is observed in most cells and tissues; however, translation into HLA-G protein is restricted to trophoblasts in the placenta, where it participates in promoting tolerance at the fetal-maternal interface. HLA-G is also expressed by thymic epitelial, cornea, mesenchymal stem cells, nail matrix, pancreatic beta cells, erythroid, and endothelial precursors. HLA-G can be neo-expressed in adult tissues in pathological conditions, and its expression has been documented autoimmune disorders, viral infections, and cancer. In the latter setting de novo HLA-G expression is associated with the capability of tumor cells to evade the immune control. In the last decade it has become evident that HLA-G expression on T cells and antigenpresenting cells confers to these cells tolerogenic properties. This Research Topic focused on i) summarizing updated clinical and immunological evidences that HLA-G expression is associate with beneficial or detrimental tolerance, ii) gathering new insights into the mechanisms governing the expression of HLA-G in healthy and pathological conditions, such as pre-eclampsia, and iii) examining the mechanisms underlying HLA-G mediated tolerance. 517 $aHLA-G-mediated Immune Tolerance 606 $aMedicine$2bicssc 610 $aAutoimmunity 610 $aCancer 610 $aExosomes 610 $aHLA-G 610 $aImmuno-modulation 610 $aInfections 610 $apolymorphisms 610 $aPre-Eclampsia 610 $aPregnancy 610 $atolerance 615 7$aMedicine 700 $aSilvia Gregori$4auth$01320412 702 $aJoel LeMaoult$4auth 906 $aBOOK 912 $a9910220053103321 996 $aHLA-G-mediated Immune Tolerance: Past and New Outlooks$93034276 997 $aUNINA